Abstract

BackgroundDenosumab treatment was shown to decrease the risk of vertebral and nonvertebral fracture in postmenopausal women with osteoporosis in the 3-year FREEDOM trial. The 7-year FREEDOM Extension is an open-label...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
OP0306 Ten Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Results from The Freedom Extension Trial
H Bone ... R Wagman
Annals of the Rheumatic Diseases | VOL. 75
H Bone, et. al.H Bone ... R Wagman
01 Jun 2016
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Roland Chapurlat ... Kurt Lippuner
The Lancet Diabetes & Endocrinology | VOL. 5
Roland Chapurlat, et. al.Roland Chapurlat ... Kurt Lippuner
22 May 2017
SAT0463 Effect of Eight Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Five-Year Results from the Freedom Extension
E Franek ... H.G Bone
Annals of the Rheumatic Diseases | VOL. 73
E Franek, et. al.E Franek ... H.G Bone
01 Jun 2014
Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
George Theodore ... Silvina Levis
Journal of managed care pharmacy : JMCP | VOL. 18
George Theodore, et. al.George Theodore ... Silvina Levis
01 May 2012
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers